Search results
Showing 136 to 150 of 292 results for breast cancer
Awaiting development [GID-TA11403] Expected publication date: TBC
In development [GID-TA11402] Expected publication date: TBC
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
- Update information
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
Osteoporosis: assessing the risk of fragility fracture (CG146)
This guideline covers assessing the risk of fragility fracture in people aged 18 and over with osteoporosis. It aims to provide guidance on the selection and use of risk assessment tools in the care of adults at risk of fragility fractures in all NHS settings.
This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. Tests and treatments covered include excision biopsy, radiotherapy, immunochemotherapy and stem cell transplantation.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer in adults.
Awaiting development [GID-TA10896] Expected publication date: TBC
Awaiting development [GID-TA11342] Expected publication date: TBC
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
Discontinued [GID-TAG403]
Awaiting development [GID-TA11487] Expected publication date: TBC
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Evidence-based recommendations on olaparib (Lynparza) with abiraterone for untreated hormone-relapsed metastatic prostate cancer in adults.